Omega Healthcare Investors (OHI) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
9 Jul, 2026Executive summary
Q4 2025 adjusted FFO was $0.80 per share and FAD was $0.76 per share, reflecting strong revenue and EBITDA growth driven by acquisitions and portfolio management.
Full-year 2025 net income was $609 million ($1.94 per share), up from $418 million ($1.55 per share) in 2024, with AFFO and FAD both growing over 8% year-over-year.
The company closed two RIDEA transactions totaling $80 million, expanded its Saber relationship, and entered the Canadian market while deleveraging the balance sheet.
By year-end, Saber is expected to become the largest revenue source, and the tenant credit profile and balance sheet are projected to be the strongest in company history.
CEO highlighted strong FAD per share growth and reduced leverage to the lowest level in company history.
Financial highlights
Q4 2025 revenue was $319 million, up from $279 million in Q4 2024; full-year revenues were $1.19 billion, up from $1.05 billion in 2024.
Q4 net income was $172 million ($0.55 per share), up from $116 million ($0.41 per share) year-over-year.
Adjusted FFO for Q4 was $250 million ($0.80 per share); FAD was $238 million ($0.76 per share); full-year AFFO was $946 million ($3.10 per share), and FAD was $903 million ($2.96 per share).
Dividend payout ratios: 84% for AFFO and 88% for FAD; dividends declared per share were $0.67 for Q4 and $2.68 for the year.
Total assets at year-end were $10.05 billion, with total equity of $5.44 billion.
Outlook and guidance
2026 full-year Adjusted FFO guidance is $3.15–$3.25 per share, reflecting completed investments as of early February and scheduled loan repayments and asset sales.
Guidance assumes $15–$25 million in asset sales per quarter and does not include additional investments beyond those announced.
High end of guidance range includes potential additional cash from Maplewood and other operators, as well as timing of loan repayments.
Guidance is subject to assumptions about operator performance, asset sales, and no major market or interest rate changes.
Latest events from Omega Healthcare Investors
- High-yield, diversified SNF REIT with strong growth, stable returns, and robust ESG focus.OHI
Investor presentation24 Jul 2026 - Q3 2025 saw higher earnings, raised AFFO guidance, and expanded investment activity.OHI
Q3 20259 Jul 2026 - Q4 saw strong financial growth, low leverage, and a robust U.K.-driven investment pipeline.OHI
Q4 20248 Jul 2026 - Board and auditor approvals, asset sale rationale, and dividend policy updates highlighted.OHI
AGM 202610 Jun 2026 - Largest SNF REIT, strong financials, poised for growth with demographic tailwinds.OHI
Investor presentation3 Jun 2026 - CEO and CFO transitions in 2026 include succession plans, incentives, and consulting agreements.OHI
Proxy filing21 May 2026 - Q1 2026 saw strong earnings growth, higher AFFO, and increased guidance amid robust investment activity.OHI
Q1 202629 Apr 2026 - Proxy details strong 2025 results, performance-based pay, and leadership in ESG and governance.OHI
Proxy filing21 Apr 2026 - Key votes include director elections, auditor ratification, and executive pay approval.OHI
Proxy filing21 Apr 2026